Zai Lab Limited (ZLAB)
(Delayed Data from NSDQ)
$16.25 USD
0.00 (0.00%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $16.27 +0.02 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZLAB 16.25 0.00(0.00%)
Will ZLAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZLAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLAB
Best Momentum Stocks to Buy for July 10th
New Strong Buy Stocks for July 10th
ZLAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
Other News for ZLAB
Zai Lab’s Solid Market Performance and Growth Prospects Justify Buy Rating
3 Small-Cap Stocks with Big Potential, Say Analysts (8/13/24)
Buy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline Developments
ClearBridge Global Growth Strategy Q2 2024 Commentary
ClearBridge International Growth ACWI Ex-US Strategy Q2 2024 Commentary